MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Rigel Pharmaceuticals Accounts Receivables 2011-2026 | RIGL
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Rigel Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.6 M | 30.6 M | 40.3 M | 15.5 M | 16 M | 10.1 M | 4.08 M | - | - | 203 K | 5.75 M | 5.75 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.6 M | 203 K | 17 M |
Quarterly Accounts Receivables Rigel Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.9 M | 39.9 M | 41.5 M | 30.6 M | 28.9 M | 27.5 M | 23.5 M | 20.8 M | 29.4 M | 40.3 M | 15.5 M | - | 15.2 M | 15.5 M | 15 M | 17.4 M | 142 M | 16 M | 16 M | 16 M | 16 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 4.08 M | 4.08 M | 4.08 M | 4.08 M | - | - | - | - | - | - | 95 K | 195 K | 203 K | 203 K | 203 K | 203 K | 5.75 M | 5.75 M | 5.75 M | 5.75 M | 5.75 M | 5.75 M | 5.75 M | 5.75 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 142 M | 95 K | 17.1 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Apellis Pharmaceuticals
APLS
|
366 M | $ 20.29 | -1.98 % | $ 2.56 B |  USA |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 0.8 | -5.3 % | $ 4.36 M | China |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 166.0 | -0.23 % | $ 8.26 B | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
Certara
CERT
|
104 M | $ 7.22 | 2.34 % | $ 1.16 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
126 M | $ 23.78 | -0.42 % | $ 2.91 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
26 K | $ 18.17 | 1.57 % | $ 873 M | USA |
 |
Adverum Biotechnologies
ADVM
|
886 K | - | - | $ 86.2 M | USA |
 |
Eton Pharmaceuticals
ETON
|
3.41 M | $ 17.9 | -1.38 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
287 M | $ 40.5 | -1.29 % | $ 11 B | USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
25 M | $ 1.02 | -0.33 % | $ 74.9 M | USA |
 |
Genmab A/S
GMAB
|
34 M | $ 27.66 | -6.71 % | $ 17.7 B |  Danmark |
 |
Halozyme Therapeutics
HALO
|
426 M | $ 68.58 | -1.82 % | $ 8.22 B | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
96.8 M | $ 28.32 | -2.01 % | $ 1.63 B | USA |
 |
ImmuCell Corporation
ICCC
|
3.77 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
800 K | $ 3.27 | -2.1 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
3.43 M | $ 28.57 | -2.16 % | $ 1.66 B | USA |
 |
Immunovant
IMVT
|
2.08 M | $ 27.09 | -2.38 % | $ 4.11 B | USA |
 |
Inhibrx
INBX
|
373 K | $ 76.39 | -1.42 % | $ 3.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
66.8 K | $ 0.8 | -2.44 % | $ 1.96 M | Canada |